Anti-factor H antibody associated hemolytic uremic syndrome following SARS-CoV-2 infection
Priyanka Khandelwal(Chacha Nehru Bal Chikitsalaya), Arvind Bagga(All India Institute of Medical Sciences), Sudarsan Krishnasamy(All India Institute of Medical Sciences), Srinivasavaradan Govindarajan(All India Institute of Medical Sciences), Binata Marik(All India Institute of Medical Sciences), Pankaj Hari(Indian Council of Medical Research), Aditi Sinha, Manish Kumar(Sterling Hospitals)
Cited by 20
Related Papers
Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome
|Journal of the American Society of Nephrology|2004|415
Clinical Features of Anti-Factor H Autoantibody–Associated Hemolytic Uremic Syndrome
|Journal of the American Society of Nephrology|2010|296
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|256
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
|Kidney International|2013|216
Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome
|Clinical Journal of the American Society of Nephrology|2010|203